GSK Receives Positive CHMP Opinion Recommending Authorisation of Daprodustat for Symptomatic Anaemia Associated With Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis
June 27, 2023
June 27, 2023
LONDON, England, June 27 -- GlaxoSmithKline, a biopharmaceutical company, issued the following news release on June 26, 2023:
GSK plc (LSE/NYSE: GSK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending authorisation of daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of symptomatic anaemia associated with chronic kidney disease . . .
GSK plc (LSE/NYSE: GSK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending authorisation of daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of symptomatic anaemia associated with chronic kidney disease . . .